CPRX•benzinga•
Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals with Overweight Rating, Announces Price Target of $35
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga